Gala vs Shed: Which GLP-1 Provider Is Better?
By Iacob Pastina, Independent Researcher
Shed beats Gala overall, scoring 7.8/10 vs 7/10. Gala is more affordable at $149/mo vs $199/mo. Choose Gala for users who want low-cost compounded tirzepatide and a built-i. Choose Shed for users who want fast delivery and a streamlined compounded gl.
A side-by-side comparison of Gala and Shed covering pricing, scores, medication types, insurance, and more to help you decide.
Gala
#40 of 42Telehealth platform offering compounded semaglutide and tirzepatide at competitive pricing, plus a paid path to brand semaglutide. Differentiator: a dedicated iOS GLP-1 tracker app for users who want to log dosing, weight, and side effects in one place.
Visit GalaShed
#16 of 42Newer GLP-1 provider focused on speed and simplicity — fast approvals, fast shipping, and a clean user experience at a competitive price point.
Visit Shed| Feature | Gala | Shed |
|---|---|---|
| Our Score | 7/10 | 7.8/10 |
| Starting Price | $149/mo | $199/mo |
| Medication Type | Both | Both |
| Insurance Accepted | No | No |
| Best For | Users who want low-cost compounded tirzepatide and a built-in iOS tracker app for daily progress logging | Users who want fast delivery and a streamlined compounded GLP-1 experience |
| Ranking | #40 | #16 |
Pros & Cons Compared
Gala
Pros
- +Compounded tirzepatide as low as $149/mo on the longest commitment plan — among the cheapest tirz options on the market
- +$199/mo entry pricing on a 3-month plan for compounded semaglutide — competitive in the mid-tier
- +Dedicated 'Gala GLP-1 Tracker' iOS app for dosing, weight, and side-effect logging — uncommon among compounded-only platforms
- +Both semaglutide and tirzepatide available, plus a brand-name semaglutide path for users who specifically want FDA-approved
Cons
- −Brand-name semaglutide pricing ($1,299/mo) is significantly above market — NovoCare direct pricing for Wegovy is $349/mo
- −Mixed Trustpilot reviews mention dosing inconsistencies and slow customer service responsiveness
- −Newer brand (Delaware-registered, limited public company history) — less track record than established platforms like Henry Meds or Sprout
- −No published lab panels or specialty clinical oversight — state-licensed prescriber review is the standard, not differentiated
Shed
Pros
- +Industry-leading delivery speed — most patients receive medication within 2-3 days of enrollment
- +$149/mo is competitively priced for an all-inclusive compounded program with good support
- +Streamlined onboarding with no video call — approved and shipped faster than most competitors
- +Clean, modern UX with real-time shipping tracking and easy provider messaging
Cons
- −Compounded semaglutide and tirzepatide only — no brand-name options
- −Newer company (founded 2024) with limited track record and outcome data
- −No insurance billing and no FSA/HSA superbills currently available
- −Clinical support is responsive but less proactive than premium platforms
Our Verdict
Shed edges out Gala with a score of 7.8/10 vs 7/10. If budget is your priority, Gala starts at $149/mo compared to Shed's $199/mo. Choose Gala if you want: users who want low-cost compounded tirzepatide and a built-in ios tracker app for daily progress logging. Choose Shed if you want: users who want fast delivery and a streamlined compounded glp-1 experience.